Reuters reports that Moderna (NASDAQ:MRNA) announced Monday it is lowering its 2025 sales forecast by $1 billion due to weak demand for its COVID-19 vaccines and a slower rollout of its new respiratory syncytial virus (RSV) shot.
The company now expects annual revenue between $1.5 billion and $2.5 billion, primarily in the latter half of the year. That's down from its earlier estimate of $2.5 billion to $3.5 billion and below the $2.95 billion analysts had expected, based on LSEG data.
CEO Stephane Bancel said Moderna plans to cut 2025 cash costs by $1 billion, with another $500 million in reductions targeted for 2026. The company anticipates finishing 2025 with about $6 billion in cash and investments.
Moderna is banking on new products to reignite growth. It has filed for FDA approval of a combination COVID-19 and flu vaccineand expects a decision by May on its next-generation COVID-19 vaccine.The company plans to release its fourth-quarter earnings on Feb. 14.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.